CASI (NASDAQ: CASI) director lists fully vested stock options on Form 3
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
CASI Pharmaceuticals director Barbara Helene Hannelore Krebs-Pohl filed an initial Form 3 reporting existing stock option holdings. She holds two fully vested options, each covering 10,000 ordinary shares, with exercise prices of $6.41 and $2.31 per share and expirations in 2034 and 2035, all owned directly. The footnote states these options are fully vested and exercisable as of the Form 3 date, and no buy or sell transactions are reported.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Krebs-Pohl Barbara Helene Hannelore
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Option (right to buy) — 10,000 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What does the CASI (CASI) Form 3 filing by Barbara Krebs-Pohl show?
The Form 3 shows Barbara Helene Hannelore Krebs-Pohl’s existing holdings of two stock option awards, each for 10,000 CASI ordinary shares, which are fully vested and exercisable and held directly, with exercise prices of $6.41 and $2.31 per share.
What stock options does Barbara Krebs-Pohl hold in CASI (CASI)?
She holds two direct option positions, each covering 10,000 underlying ordinary shares of CASI. One has a $6.41 exercise price expiring in 2034, and the other has a $2.31 exercise price expiring in 2035, both fully vested and exercisable.
Are the CASI (CASI) options held by Barbara Krebs-Pohl fully vested?
Yes, the footnote states the options are fully vested and exercisable as of the Form 3 date. This means Krebs-Pohl can exercise each option for 10,000 ordinary shares at the stated exercise prices, subject to their future expiration dates.
Is Krebs-Pohl’s ownership in CASI (CASI) direct or through another entity?
The Form 3 labels her ownership as direct for both option positions. There are no footnotes indicating that the options are held through a trust, LLC, or other related entity, so the reported derivative holdings are attributed directly to her.